Summary

• No prospective, randomized, head-to-head clinical trials comparing the efficacy and safety of AKEEGA with talazoparib have been conducted.
• Results from a matching-adjusted indirect comparison (MAIC) study that utilized data from the following phase 3 registrational studies in patients with first-line metastatic castration-resistant prostate cancer have been reported:¹ 
  • MAGNITUDE (AKEEGA and androgen deprivation therapy [ADT] vs placebo/abiraterone acetate plus prednisone [AAP] and ADT; homologous recombination repair [HRR] mutation population)
  • TALAPRO-2 (talazoparib plus enzalutamide and ADT vs placebo plus enzalutamide and ADT; all-comers population)
  • PROpel (olaparib plus AAP and ADT vs placebo plus AAP and ADT; all-comers population)

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 17 July 2025. Summarized in this response are relevant data pertaining to this topic in patients with prostate cancer.